NCT03179943View on ClinicalTrials.gov

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

July 12, 2020

Study Completion Date

July 31, 2022

Conditions
Urothelial Carcinoma
Interventions
DRUG

Atezolizumab

Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.

DRUG

Guadecitabine

Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

21287

Johns Hopkins University School of Medicine, Baltimore

90033

USC Norris Hospital and Clinics, Los Angeles

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Van Andel Research Institute

OTHER

lead

Fox Chase Cancer Center

OTHER